Furthermore, we present clear indication that high levels of DNMT1 in tumor cells as well as their adjacent stromal fibroblasts predict poor survival post-neoadjuvant treatment of locally advanced breast cancer patients. This evidence concerns the gene DNMT1 and breast carcinoma.